Principia is bringing transformative therapies to patients with serious immune-mediated diseases by changing the way small molecules are developed.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $62.5M
Founded date: 2008
Investors 5
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | Access Bio... | accessbio-... |
| - | Sofinnova ... | sofinnova.... |
| - | Lightstone... | lightstone... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.04.2014 | Series B | $50M | - |
| 29.10.2012 | Series A | $12.5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 14.05.2019 | Principia Biopharma Announces First Patient Dosed In Sanofi’s Phase 2b Trial Of SAR442168 In Multiple Sclerosis, Triggering $30 Million Milestone | - |
| 22.04.2014 | Principia Biopharma Secures $50M in Series B | SOUTH SAN FRANCISCO, CA, Principia Biopharma today announced that it has secured a $50 million Series B private financing round. >> Click here for more funding data on Principia Biopharma >> To export Principia Biopharma fun... |
| 22.04.2014 | Principia Biopharma Raises $50M in Series B Financing | Principia Biopharma Inc., a South San Francisco, CA-based biopharmaceutical company, raised $50m in Series B financing. The round was led by Sofinnova Ventures, with participation from existing investors Morgenthaler Ventures, New Leaf Vent... |
| 29.10.2012 | Principia Biopharma Raises $12.5M | Principia Biopharma, Inc., a South San Francisco, CA-based biopharmaceutical company focused on advancing medicines in immunology, autoimmune diseases, and oncology, received its $12.5m second tranche of funding after meeting milestone obli... |
| 29.10.2012 | Principia Biopharma Inks $12.5M Series A-2 | SAN FRANCISCO, CA, Privately-held biopharmaceutical company focused on advancing best-in-class medicines in immunology, autoimmune diseases, and oncology, announced that it successfully met its milestone obligations and received its secon... |